1. Home
  2. GKOS vs KRYS Comparison

GKOS vs KRYS Comparison

Compare GKOS & KRYS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Glaukos Corporation

GKOS

Glaukos Corporation

HOLD

Current Price

$116.08

Market Cap

5.4B

Sector

Health Care

ML Signal

HOLD

Logo Krystal Biotech Inc.

KRYS

Krystal Biotech Inc.

HOLD

Current Price

$239.81

Market Cap

6.3B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
GKOS
KRYS
Founded
1998
2015
Country
United States
United States
Employees
N/A
N/A
Industry
Medical/Dental Instruments
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
5.4B
6.3B
IPO Year
2015
2017

Fundamental Metrics

Financial Performance
Metric
GKOS
KRYS
Price
$116.08
$239.81
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
13
9
Target Price
$125.54
$214.22
AVG Volume (30 Days)
865.8K
326.2K
Earning Date
10-29-2025
11-03-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
275.72
EPS
N/A
6.66
Revenue
$469,820,000.00
$373,164,000.00
Revenue This Year
$31.15
$36.14
Revenue Next Year
$24.15
$41.80
P/E Ratio
N/A
$36.15
Revenue Growth
30.38
54.51
52 Week Low
$73.16
$122.80
52 Week High
$163.71
$248.60

Technical Indicators

Market Signals
Indicator
GKOS
KRYS
Relative Strength Index (RSI) 76.42 67.80
Support Level $105.88 $231.69
Resistance Level $116.72 $248.60
Average True Range (ATR) 3.26 8.08
MACD 0.07 -0.51
Stochastic Oscillator 94.61 75.49

Price Performance

Historical Comparison
GKOS
KRYS

About GKOS Glaukos Corporation

Glaukos Corp is an ophthalmic pharmaceutical and medical technology company focused on developing novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders, and retinal diseases. It has commenced commercialization activities for iDose TR, a first-of-its-kind, long-duration, intracameral procedural pharmaceutical implant designed to continuously deliver glaucoma drug therapy inside the eye for extended periods of time. The company also offer commercially a proprietary bio-activated pharmaceutical therapy for the treatment of a rare corneal disorder, keratoconus. It has three primary commercialized micro-scale surgical device products designed to treat glaucoma: the iStent, the iStent inject W, and the iStent infinite.

About KRYS Krystal Biotech Inc.

Krystal Biotech Inc is engaged in the healthcare sector in the United States. It is focused on the development of easy-to-use, redosable gene therapies to improve the lives of patients living with debilitating diseases. The company used its proprietary gene therapy platform, STAR-D to develop treatments for rare or orphan dermatological indications caused by the absence of or a mutation in a single gene. It plans to leverage its platform to expand its pipeline to include other dermatological indications in the future. The company has one operating segment, which is the business of developing and commercializing pharmaceutical products.

Share on Social Networks: